Lilly FASTens On SGX Following Shareholder Vote To Complete Acquisition
This article was originally published in The Pink Sheet Daily
Executive Summary
Lilly acquires SGX, with its “FAST” fragment-based drug discovery platform and preclinical oncology portfolio; new subsidiary can move beyond financial woes.